277 related articles for article (PubMed ID: 10235612)
1. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon.
Almasio PL; Di Marco V; Bonura C; Fuschi P; Camma C; Lo Iacono O; Artini M; Natoli C; Di Stefano R; Levrero M; Craxi A
Dig Dis Sci; 1999 May; 44(5):1013-9. PubMed ID: 10235612
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.
Di Marco V; Almasio P; Vaccaro A; Ferraro D; Parisi P; Cataldo MG; Di Stefano R; Craxì A
J Hepatol; 2000 Sep; 33(3):456-62. PubMed ID: 11020002
[TBL] [Abstract][Full Text] [Related]
3. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
4. alpha-Interferon retreatment of patients with chronic hepatitis C.
Rabinovitz M; Block G; Finkelstein SD
Am J Gastroenterol; 1996 Aug; 91(8):1523-6. PubMed ID: 8759654
[TBL] [Abstract][Full Text] [Related]
5. Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course of interferon-alpha 2b.
Tong MJ; Blatt LM; Tong LT; Sayadzadeh K; Conrad A
J Viral Hepat; 1998 Sep; 5(5):323-31. PubMed ID: 9795916
[TBL] [Abstract][Full Text] [Related]
6. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
[TBL] [Abstract][Full Text] [Related]
7. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
[TBL] [Abstract][Full Text] [Related]
8. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
[TBL] [Abstract][Full Text] [Related]
9. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C.
Di Marco V; Lo Iacono O; Cammà C; Almasio PL; Vaccaro A; Fuschi P; Giunta M; Fabiano C; Pagliaro L; Craxì A
J Med Virol; 1997 Jan; 51(1):17-24. PubMed ID: 8986944
[TBL] [Abstract][Full Text] [Related]
11. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Keeffe EB; Hollinger FB
Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
Pol S; Couzigou P; Bourlière M; Abergel A; Combis JM; Larrey D; Tran A; Moussalli J; Poupon R; Berthelot P; Bréchot C
J Hepatol; 1999 Jul; 31(1):1-7. PubMed ID: 10424277
[TBL] [Abstract][Full Text] [Related]
14. Tailoring interferon dose and monitoring viral load in hepatitis C virus genotype 1b infected patients: a pilot study.
Colombatto P; Baldi M; Oliveri F; Randone A; Bonino F; Brunetto MR
Dig Liver Dis; 2000 Apr; 32(3):211-6. PubMed ID: 10975771
[TBL] [Abstract][Full Text] [Related]
15. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
[TBL] [Abstract][Full Text] [Related]
17. High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial.
Boucher EJ; Jacquelinet S; Canva V; Turlin B; Jacquelinet C; Colimon R; Deugnier Y; Guyader D; Brissot P
Liver Int; 2003 Aug; 23(4):255-61. PubMed ID: 12895265
[TBL] [Abstract][Full Text] [Related]
18. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
[TBL] [Abstract][Full Text] [Related]
19. Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
Steindl-Munda P; Ferenci P; Brunner H; Nachbaur K; Datz C; Gschwantler M; Hofer H; Stauber R; Hackl F; Jessner W; Rosenbeiger M; Gangl A; Vogel W;
Liver Int; 2003 Aug; 23(4):269-75. PubMed ID: 12895267
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
